NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free TMDX Stock Alerts $88.65 -1.95 (-2.15%) (As of 03:26 PM ET) Add Compare Share Share Today's Range$86.59▼$90.9750-Day Range$70.86▼$95.6552-Week Range$36.42▼$99.63Volume420,251 shsAverage Volume686,551 shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$102.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TransMedics Group alerts: Email Address TransMedics Group MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside16.9% Upside$102.00 Price TargetShort InterestBearish18.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 9 Articles This WeekInsider TradingSelling Shares$9.97 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.14) to $0.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.81 out of 5 starsMedical Sector820th out of 909 stocksElectromedical Equipment Industry16th out of 18 stocks 2.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTransMedics Group has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.31% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in TransMedics Group has recently increased by 10.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 2.0 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for TransMedics Group this week, compared to 4 articles on an average week.Search InterestOnly 12 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,972,971.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow in the coming year, from ($0.14) to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -113.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -113.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 20.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About TransMedics Group Stock (NASDAQ:TMDX)TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More TMDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Stock News HeadlinesApril 19, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 SharesApril 14, 2024 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 12,000 Shares of StockApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 11, 2024 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 15,512 Shares of StockApril 6, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $397,540.92 in StockApril 3, 2024 | insidertrades.comStephen Gordon Sells 15,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockApril 20, 2024 | americanbankingnews.comWaleed H. Hassanein Sells 4,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockApril 18, 2024 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from BrokeragesApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - TMDXApril 16, 2024 | finance.yahoo.comTransMedics to Report First Quarter 2024 Financial Results on April 30, 2024April 15, 2024 | finance.yahoo.comThere's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On CapitalApril 12, 2024 | investorplace.comWall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024April 12, 2024 | investing.comTransMedics group exec sells over $1.79 million in company stockApril 12, 2024 | investorplace.com3 Must-Own Stocks for Sustained Growth Over the Next 18 MonthsApril 11, 2024 | investorplace.comThe 3 Most Promising MedTech Stocks to Invest In NowApril 11, 2024 | finance.yahoo.comHeart And Lung Transplants Drive Medical Stock Higher As S&P 500 FizzlesApril 11, 2024 | investors.comOrgan Transplant Stock Surges Past Buy Point Even As S&P 500 FizzlesApril 8, 2024 | prnewswire.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)March 25, 2024 | markets.businessinsider.comTransMedics Group: Operational Efficiency and Market Positioning Propel Buy RatingMarch 22, 2024 | seekingalpha.comTransMedics: Strong Business, Fully Valued StockMarch 19, 2024 | finance.yahoo.comTMDX Jul 2024 135.000 callMarch 12, 2024 | seekingalpha.comTransMedics Group: Huge Opportunity In Organ TransplantsMarch 5, 2024 | finance.yahoo.comJim Cramer’s Latest Lightning Round: 11 Stock RecommendationsMarch 3, 2024 | markets.businessinsider.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDXMarch 3, 2024 | finance.yahoo.comBrokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New ForecastsMarch 3, 2024 | fool.com2 No-Brainer Growth Stocks to Buy With $100 in MarchSee More Headlines Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/24/2024Next Earnings (Confirmed)4/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees584Year FoundedN/APrice Target and Rating Average Stock Price Target$102.00 High Stock Price Target$110.00 Low Stock Price Target$95.00 Potential Upside/Downside+12.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,030,000.00 Net Margins-10.36% Pretax Margin-11.04% Return on Equity-2.35% Return on Assets-0.60% Debt Debt-to-Equity Ratio3.69 Current Ratio9.30 Quick Ratio8.49 Sales & Book Value Annual Sales$241.62 million Price / Sales12.23 Cash Flow$0.15 per share Price / Cash Flow607.78 Book Value$4.20 per share Price / Book21.51Miscellaneous Outstanding Shares32,710,000Free Float30,521,000Market Cap$2.95 billion OptionableOptionable Beta1.99 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Waleed H. Hassanein M.D. (Age 56)Founder, President, CEO & Director Comp: $1.82MMr. Stephen Gordon (Age 56)CFO, Treasurer & Secretary Comp: $909.62kMr. Mark AndersonSenior Director of Technology DevelopmentKey CompetitorsLivaNovaNASDAQ:LIVNCONMEDNYSE:CNMDIntegerNYSE:ITGRInModeNASDAQ:INMDSoleno TherapeuticsNASDAQ:SLNOView All CompetitorsInsiders & InstitutionsRaymond James Financial Services Advisors Inc.Bought 10,325 shares on 4/23/2024Ownership: 0.084%Venturi Wealth Management LLCBought 400 shares on 4/23/2024Ownership: 0.001%Allspring Global Investments Holdings LLCBought 21,737 shares on 4/18/2024Ownership: 2.232%Wasatch Advisors LPBought 434,971 shares on 4/18/2024Ownership: 1.330%Waleed H HassaneinSold 4,000 sharesTotal: $380,480.00 ($95.12/share)View All Insider TransactionsView All Institutional Transactions TMDX Stock Analysis - Frequently Asked Questions Should I buy or sell TransMedics Group stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks. What is TransMedics Group's stock price target for 2024? 7 Wall Street analysts have issued twelve-month price objectives for TransMedics Group's stock. Their TMDX share price targets range from $95.00 to $110.00. On average, they predict the company's share price to reach $102.00 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts. How have TMDX shares performed in 2024? TransMedics Group's stock was trading at $78.93 on January 1st, 2024. Since then, TMDX stock has increased by 10.6% and is now trading at $87.26. View the best growth stocks for 2024 here. When is TransMedics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our TMDX earnings forecast. How can I listen to TransMedics Group's earnings call? TransMedics Group will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings data on Monday, February, 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. The business earned $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative trailing twelve-month return on equity of 2.35% and a negative net margin of 10.36%. The company's revenue was up 158.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.21) EPS. What ETFs hold TransMedics Group's stock? ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Innovator IBD 50 ETF (FFTY), Clough Select Equity ETF (CBSE), Clough Long/Short Equity ETF (CBLS), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BNY Mellon Innovators ETF (BKIV), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Principal Healthcare Innovators ETF (BTEC). What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $360.0 million-$370.0 million, compared to the consensus revenue estimate of $330.2 million. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS). When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (2.23%), Wasatch Advisors LP (1.33%), Raymond James Financial Services Advisors Inc. (0.08%), Park Avenue Securities LLC (0.03%), Los Angeles Capital Management LLC (0.02%) and Venturi Wealth Management LLC (0.00%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TMDX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
